CSI Market
Sign In | Register

Nymox Pharmaceutical (NYMX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access NYMX Annual Balance Sheets →
A period-by-period view of the balance sheet from Nymox Pharmaceutical to Dec 31 2023 helps clarify how Dec 31 2024's financial structure has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2024)
0 0 0 (Dec 31 2023)
Assets
Cash & cash equivalent0.07
Security Deposit0.04
Cash & Short-term Investments0.00
Other Receivables0.03
Other Current Assets0.52
Total Current Assets0.65
Equipment/Property/Plant Net0.00
Total Assets0.65
Liabilities
Accounts Payable4.14
Other Liabilities, Current7.43
Total Current Liabilities7.43
Total Long-term Debt0.00
Total Liabilities7.43
Stockholders' Equity
Other Equity-6.78
Common Stockholder's Equity-6.78
Total Stockholder's Equity-6.78
Liabilities & Stockholder's Equity0.65
4 historic quarters locked

Sign in to unlock the full Nymox Pharmaceutical balance sheet history.

Sign In Create Free Account

About Nymox Pharmaceutical Corp Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 20-F filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 20-F (Period: 20241231)
  • Filed with the SEC: June 3, 2025
  • Source: nymox_20f.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001640334-25-000972

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.